MESO Price Prediction Next Week
Analysis and Insights
News and Event Impact:
Mesoblast (MESO) has recently been added to the S&P/ASX 200 Index, enhancing its market visibility and potentially attracting more institutional investors. Additionally, the company has received FDA approval for its graft-versus-host disease therapy, which has positively impacted market sentiment and led to a 13% stock price increase.
Technical Indicators:
- RSI (14): 32.98 (oversold territory, indicating potential buy signal)
- MACD: -1.17 (bearish momentum, but showing signs of stabilization)
- Fibonacci Levels: Pivot at 13.73, with resistance at 14.78 and support at 12.68
Price Prediction and Recommendation:
Based on the oversold RSI and positive news sentiment, MESO is expected to rebound. The stock is likely to test the Fibonacci resistance level of 14.78 next week.
Predicted Price: $14.78
Recommendation: Buy
MESO Similar Chart Price Prediction
The price of MESO is predicted to go up 8.38%, based on the high correlation periods with CVNA. The similarity of these two price pattern on the periods is 98.49%.
MESO
CVNA
Up: 8.38%Similarity: 98.49%
MESO Revenue Forecast
MESO EPS Forecast
MESO FAQs
What is MESO revenue forecast for next quarter？
MESO Analyst's Forecast
David Stanton
Jefferies
Strong Buy → Hold
2024-12-23
Price Target
n/a
Downside
0%
Jefferies downgraded Mesoblast to Hold from Buy with a price target of A$2.30, up from A$1.10. The firm updated the company's for the FDA'ss recent approval of Ryoncil in pediatric steroids-refractory acute graft-versus-host disease patients. While the market size is only 375 pediatric patients per year in the U.S., expansion of this indication is possible in adults if the upcoming adult trial is positive, the analyst tells investors in a research note. Jefferies continues to assume full U.S. reimbursement approval at the start of fiscal 2026. However, after Mesoblast's recent share price appreciation, the firm downgraded the shares on valuation.
Jason McCarthy
Maxim Group
Hold → Strong Buy
2024-09-24
Price Target
$12
Upside
+65.06%
